New antiepileptic drugs that are second generation to existing antiepileptic drugs

Bibliography

• BIALER M, JOHANNESSEN SI, KUPFERBERG H et al.: Progress report on new antiepileptic drugs: a summary of the seventh Eilat conference on new antiepileptic drugs (EILAT VII). Epilepsy Res. (2004) 61:1-48.
   PubMed Web of Science ®Google Scholar
• BIALER M, WALKER MC, SANDER JWS: Pros and cons for the development of new antiepileptic drugs. CNS Drugs (2002) 16:285-289.
   PubMed Web of Science ®Google Scholar
• PERUCCA E: The new antiepileptic drugs: pharmacological and clinical aspects. Curr. Pharm. Design (2000) 6:839-860.
   PubMed Web of Science ®Google Scholar
• BIALER M: New antiepileptic drugs currently in clinical trials: is there a strategy in their development? Ther. Drug Monit. (2002) 24:85-90.
   PubMed Web of Science ®Google Scholar
• WALKER MC, SANDER JWS: The impact of new antiepileptic drugs on the prognosis of epilepsy: seizure freedom should be the ultimate goal. Neurology (1996) 46:912-914.
   PubMed Web of Science ®Google Scholar
• ISOHERRANEN N, YAGEN B, BIALER M: New CNS-active drugs which are second generation valproic acid: can they lead to development of the magic bullet? Curr. Opin. Neurol. (2003) 16:203-211.
   PubMed Web of Science ®Google Scholar
• LYNCH B, LAMBENG N, NOCKAS K et al.: The synaptic vesicle protein SV2A is the binding site for the antiepileptic levetiracetam. Proc. Natl. Acad. Sci. (2004) 101:9861-9866.
   PubMed Web of Science ®Google Scholar
• THOMPSON CD, KINTER MT, MacDONALD TL: Synthesis and in vitro reactivity of 3-carbamoyl-2-phenylpropionaldehyde and 2-phenylpropenal; putuative reactive metabolites of felbamate. Chem. Res. Toxicol. (1996) 9:1225-1229.
   PubMed Web of Science ®Google Scholar
• BIALER M, JOHANNESSEN SI, KUPFERBERG HJ et al.: Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference on new antiepileptic drugs (EILAT IV). Epilepsy Res. (1999) 34:1-41.
   PubMed Web of Science ®Google Scholar
• VOLOSOV A, XIANDONG S, PERUCCA E et al.: Enantioselective pharmacokinetics of 10-hydroxy carbazepine following oral administration of oxcarbazepine to healthy Chinese subjects. Clin. Pharmacol. Ther. (1999) 66:547-553.
   PubMed Web of Science ®Google Scholar
• BIALER M: Oxcarbazepine: chemistry, biotransformation and pharmacokinetics. In: Antiepileptic Drugs, Levy RH, Mattson RH, Meldrum BS, Perucca E (Eds), Lippincott, Philadelphia, USA (2002) 5:459-465.
   Google Scholar
• FLESCH G, CZENDLIK G, EHRHART E et al.: Pharmacokinetics of two enantiomers of the monohydroxy derivatives of oxcarbazepine in man. Eur. J. Pharm. Sci. (1999) 8:xxii (Abstract).
   Google Scholar
• JAIN KK: An assessment of rufinamide as an anti-epileptic in comparison with other drugs in clinical development. Expert Opin. Investig. Drugs (2000) 9:829-840.
   PubMed Web of Science ®Google Scholar
• BENES J, PARADA A, FIGUEIREDO AA et al.: Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5- carboxamide derivatives. J. Med. Chem. (1999) 42:2582-2587.
   PubMed Web of Science ®Google Scholar
• ALMEIDA L, FALCAO L, MAIA J et al.: Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects. J. Clin. Phramacol. (2005) 45:1062-1006.
   PubMed Web of Science ®Google Scholar
• ALMEIDA L, SOARES DA SILVA P: Safety, tolerability and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic agent, during first administration to humans. Drugs R&D (2003) 4:269-284.
   PubMedGoogle Scholar
• ALMEIDA L, SOARES DA SILVA P: Safety, tolerability and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young humans. J. Clin. Pharmacol. (2004) 44:906-918.
   PubMed Web of Science ®Google Scholar
• HAINZL D, PARADA A, SOARES DA SILVA P: Metabolism of two new antiepileptic drugs and their principal metabolites S(+)- and R(-)-10,11-dihydro-10-hydroxy carbamazepine. Epilepsy Res. (2001) 44:197-206.
   PubMed Web of Science ®Google Scholar
• ALMEIDA L, MAIA J, SOARES DA SILVA P: A double blind, add-on, placebo-controlled exploratory trial of eslicarbazepine acetate in patients with partial-onset seizures. Epilepsia (2005) 46(Suppl. 46):167-168.
   Web of Science ®Google Scholar
• PERUCCA E: Pharmacological and therapeutic properties of valproate. A summary after 35 years of clinical experience. CNS Drugs (2002) 16:695-714.
   PubMed Web of Science ®Google Scholar
• LOSCHER W: Valproate. Birkhauser Verlag, Basel, Switzerland (1999).
   Google Scholar
• LOSCHER W: Basic pharmacology of valproate. A review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs (2002) 16:669-694.
   PubMed Web of Science ®Google Scholar
• ISOHERRANEN N, YAGEN B, BLOTNIK S et al.: Characterization of the anticonvulsant activity and pharmacokinetics of propylisopropyl acetamide and its enantiomers. Br. J. Pharmacol. (2003) 138:602-613.
   PubMed Web of Science ®Google Scholar
• SOBOL E, BIALER M, YAGEN B: Tetramethylcyclopropyl analogue of a leading antiepileptic drug, valproic acid. Synthesis and evaluation of anticonvulsant activity of its amide derivatives. J. Med. Chem. (2004) 47:4316-4326.
   PubMed Web of Science ®Google Scholar
• WINKLER I, SOBOL E, YAGEN B et al.: Efficacy of antiepileptic tetramethylcyclopropyl analogues of valproic acid amides in a rat model for neuropathic pain. Neuropharmacology (2005) 49:1110-1120.
   PubMed Web of Science ®Google Scholar
• NAU H, SIEMENS H: Differentiation between valproate-induced anticonvulsant effect, teratogenicity and hepatotoxicity. Pharm. Weekbl. Sci. (1992) 14:101-105.
   PubMedGoogle Scholar
• NAU H, HENDRICKX AG: Valproic acid teratogenesis. ISI Atlas Sci. Pharmacol. (1987) 1:52-56.
   Google Scholar
• NAU H, HAUCK R-S, EHLERS K: Valproic acid induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms. Pharmacol. Toxicol. (1991) 69:310-321.
   PubMedGoogle Scholar
• TANG W, PALATY J, ABBOTT FS: Time course of α-fluorinated valproic acid in mouse brain and serum and its effect on synaptosomal γ-aminobutyric acid levels in comparison to valproic acid. J. Pharmacol. Exp. Ther. (1997) 282:1163-1172.
   PubMed Web of Science ®Google Scholar
• TANG W, BOREL AG, FUJIMIYA T et al.: Fluorinated analogues as mechanistic probes in valproic acid hepatotoxicity: hepatic microvesicular steatosis and glutathione status. Chem. Res. Toxicol. (1995) 8:671-682.
   PubMed Web of Science ®Google Scholar
• NEUMAN MG, SHEAR NH, JACOBSON-BROWN PM et al.: CYP2E1 mediated modulation of valproic acid-induced hepatocytotoxicity. Clin. Biochem. (2001) 34:211-218.
   PubMed Web of Science ®Google Scholar
• GRILLO MP, CHIELLINI G, TONELLI M et al.: Effect of α-fluorination of valproic acid on valproyl-S-acyl-CoA formation in vivo in rats. Drug Metab. Dispos. (2001) 29:1210-1215.
   PubMed Web of Science ®Google Scholar
• BIALER M: Clinical pharmacology of valpromide. Clin. Pharmacokinet. (1991) 20:114-122.
   PubMed Web of Science ®Google Scholar
• ISOHERRANEN N, KLEIN B, ROEDER M et al.: Pharmacokinetic-pharmacodynamic relationships of (2S,3S)-valnoctamide and its stereoisomer (2R,3S)-valnoctamide in rodent models of epilepsy. Pharm. Res. (2003) 20:1293-1301.
   PubMed Web of Science ®Google Scholar
• SPIEGELSTEIN O, YAGEN B, LEVY RH et al.: Stereoselective pharmacokinetics and pharmacodynamics of propylisopropyl acetamide, a CNS-active chiral amide analog of valproic acid. Pharm. Res. (1999) 16:1582-1588.
   PubMed Web of Science ®Google Scholar
• WINKLER I, BLOTNIK S, SHIMSHONI J et al.: Efficacy of antiepileptic isomers of valproic acid and valpromide in a rat model for neuropathic pain. Br. J. Pharmacol. (2005) 146:198-208.
   PubMed Web of Science ®Google Scholar
• ISOHERRANEN N, WHITE HS, FINNELL RH et al.: Anticonvulsant profile and teratogenicity of N-methyl-tetamethylcyclopropyl carboxamide: a new antiepileptic drug. Epilepsia (2002) 43:115-126.
   PubMed Web of Science ®Google Scholar
• SOBOL E, YAGEN B, WINKLER I et al.: Pharmacokinetics and metabolism of a new potent anticonvulsant agent 2,2,3,3-tetramethylcyclopropylcarbonylurea in rats. Drug Metab. Dispos. (2005) 33:1538-1546.
   PubMed Web of Science ®Google Scholar
• OKADA A, ONISHI Y, AOKI K et al.: Teratology studies of derivatives of tetramethylcyclopropyl amide analogues of valproic acid in mice. Birth Defect. Res. (Part B) (2006) 77:1-7.
   PubMed Web of Science ®Google Scholar
• SOBOL E, YAGEN B, WHITE HS et al.: Preclinical evaluation of 2,2,3,3-tetramethylcyclopropanecarbonyl- urea, a novel second generation to valproic acid, antiepileptic drug. Neuropharmacology (Submitted).
   Google Scholar
• SHALTIEL G, SHAMIR A, SHAPIRO J et al.: Valproate decreases inositol biosynthesis. Biol. Psychiatr. (2004) 56:868-874.
   PubMed Web of Science ®Google Scholar
• ISOHERRANEN N, WOODHEAD JH, WHITE HS, BIALER M: Anticonvulsant profile of valrocemide (TV1901): a new antiepileptic drug. Epilepsia (2001) 42:831-836.
   PubMed Web of Science ®Google Scholar
• APPLEBAUM J, GAYDUK J, AGAM G et al.: Valnoctamide as valproate substitute with low teratogenic potential: double blind controlled clinical trial. Bipolar Disorder (2005) 7(Suppl. 2):30.
   Google Scholar
• BIALER M, JOHANNESSEN SI, KUPFERBERG HJ et al.: Progress report on new antiepileptic drugs: a summary of the sixth Eilat conference on new antiepileptic drugs (EILAT VI). Epilepsy Res. (2002) 51:31-71.
   PubMed Web of Science ®Google Scholar
• LABINER DM: DP-VPA. Curr. Opin. Invest. Drug. (2002) 3:921-923.
   PubMedGoogle Scholar
• DE PAULIS T: ONO-2506. Curr. Opin. Investig. Drug. (2003) 4:863-867.
   PubMedGoogle Scholar
• BLAHETA RA, CINTAL J: Anti-tumor mechanism of valproate: a novel role of an old drug. Med. Res. Rev. (2002) 22:491-511.
   Web of Science ®Google Scholar
• BLAHETA RA, NAU H, MICHAELIS M, CINTAL J: Valproate and valrpoate-analogues: potent tools to fight against cancer. Curr. Med. Chem. (2002) 9:1417-1433.
   PubMed Web of Science ®Google Scholar
• EYAL S, YAGEN B, SHIMSHONI J, BIALER M: Histone deacetylases inhibition and tumor cells cytotoxicity by CNS-active VPA constitutional isomers and derivatives. Biochem. Pharmacol. (2005) 69:1501-1508.
   PubMed Web of Science ®Google Scholar
• DWORKIN RH, KIRKPATRICK P: Pregabalin. Nat. Rev. (2005) 4:455-456.
   Google Scholar
• BELLIOTTI TR, CAPIRIS T, EKHATO V et al.: Structure–activity relationships of pregabalin analogues that target the α2-δ protein. J. Med. Chem. (2005) 48:2294-2307.
   PubMed Web of Science ®Google Scholar
• CUNDY KC, BRANCH R, CHERNOV-ROGAN T et al.: XP13512 [+/1]-1-([(α-isobutanoyloxyethoxy)- carbonyl]aminoethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporter. J. Pharmacol. Exp. Ther. (2004) 311:315-323.
   PubMed Web of Science ®Google Scholar
• CUNDY KC, ANNAMALAI T, BU L et al.: XP13512 [+/1]-1-([(α-isobutanoyloxyethoxy)- carbonyl]aminoethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys. J. Pharmacol. Exp. Ther. (2004) 311:324-333.
   PubMed Web of Science ®Google Scholar
• STEWART BH, KUGLER AH, TOMPSON PT, BOCKBRADER: A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of dose proportionality between increasing dose and drug levels in plasma. Pharm. Res. (1993) 10:276-281.
   PubMed Web of Science ®Google Scholar
• UCHINO H, KANAI Y, KIM DO K et al.: Transport of amino acid transporter 1 (LAT1): insights into the mechanism of saturable recognition. Mol. Pharmacol. (2002) 61:729-737.
   PubMed Web of Science ®Google Scholar
• CUNDY KC: Novel uses of drug transporters for drug delivery: a case study with gabapentin. Drug Transporters in ADME, Parisippany, New Jersey, USA (7 – 9 March 2005) (AAPS workshop).
   Google Scholar
• MATAGNE A, KENDA B, MICHEL P, KLITGAARD H: Ucb34714, a new pyrrolidone derivative: comparison with levetiracetam in animal models for chronic epilepsy in vivo. Epilepsia (2003) 44(Suppl. 9):260.
   Web of Science ®Google Scholar
• KENDA B, MATANGE A, TALAG P et al.: Discovery of 4-substitiuted pyrrolidone butanamides as agents with significant antiepileptic activities. J. Med. Chem. (2004) 47:530-549.
   PubMed Web of Science ®Google Scholar
• WASTERLAIN C, SUCHOMELOVA L, MATANGE A et al.: Brivaracetam is a potent anticonvulsant in experimental status epilepticus. Epilepsia (2005) 46(Suppl. 8):219-220.
   Web of Science ®Google Scholar
• RIGO JM, NGUYEN L, HANS G et al.: Seletracetam (ucb44212): effect on inhibitory and excitatory neurotransmission. Epilepsia (2005) 46(Suppl. 8):110-111.
   PubMedGoogle Scholar
• ZONA C, NIESPODZIANKY I, PIERI M et al.: Seletracetam (ucb44212), a new pyrrolidone derivative, lacks effect on Na+ currents in rat brain neurons in vitro. Epilepsia (2005) 46(Suppl. 8):116.
   Google Scholar
• PISANI A, BONSI P, MARTELLA G et al.: Seletracetam (ucb44212), a new pyrrolidone derivative, inhibits high-voltage-activated Ca2+ currents and intracellular [Ca2+] increase in rat cortical neurons in vitro. Epilepsia (2005) 46(Suppl. 8):119-120.
   Google Scholar
• MATANGE A, MICHEL P, KENDA B, KLTIGAARD H: Ucb44212, a new pyrrolidone derivative, suppresses seizures in animal models for chronic epilepsy in vivo. Epilepsia (2003) 46(Suppl. 6):121.
   Google Scholar
• MAZARATI AM, SOFIAM RD, WASTERLIN CG: Anticonvulsant and antiepileptogenic effect of fluorofelbamate in experimental status epilepticus. Seizure (2002)1:423-430.
   Web of Science ®Google Scholar
• WALLIS RA, PANIZZON KL, NIQUET J et al.: Neuroprotective effect of the anticonvulsant, fluorofelbamate. Epilepsia (2000) 14(Suppl. 7):16.
   Google Scholar
• WALKER MC, SANDER JW: New anti-epileptic drugs. Expert Opin. Investig. Drug. (1999) 8:1497-1510.
   PubMedGoogle Scholar
• KLITGAARD H: Antiepileptic drug discovery: lessons from the past and future challenges. Acta Neurol. Scand. (2005) 112(Suppl. 181):68-72.
   Web of Science ®Google Scholar
• BIALER M, TWYMAN RE, WHITE HS: Correlation between anticonvulsant-ED50 values of antiepileptic drugs in mice and rats and their therapeutic doses and plasma levels. Epilepsy Behav. (2004) 5:866-872.
   PubMed Web of Science ®Google Scholar